Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer

gan Zhang, Haichao, Xue, John, Hessler, Paul, Tahir, Stephen K., Chen, Jun, Jin, Sha, Souers, Andrew J., Leverson, Joel D., Lam, Lloyd T.
Cyhoeddwyd yn Mol Cancer (2015)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it

gan Tahir, Stephen K., Smith, Morey L., Hessler, Paul, Rapp, Lisa Roberts, Idler, Kenneth B., Park, Chang H., Leverson, Joel D., Lam, Lloyd T.
Cyhoeddwyd yn BMC Cancer (2017)

Down-regulation of Survivin by Antisense Oligonucleotides Increases Apoptosis, Inhibits Cytokinesis and Anchorage-Independent Growth

gan Chen, Jun, Wu, Wei, Tahir, Stephen K, Kroeger, Paul E, Rosenberg, Saul H, Cowsert, Lex M, Bennett, Frank, Krajewski, Stanislaw, Krajewska, Maryla, Welsh, Kate, Reed, John C, Ng, Shi-Chung
Cyhoeddwyd 2000

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

gan Ackler, Scott, Oleksijew, Anatol, Chen, Jun, Chyla, Brenda J, Clarin, Jerry, Foster, Kelly, McGonigal, Thomas, Mishra, Sasmita, Schlessinger, Sally, Smith, Morey L, Tahir, Stephen K, Leverson, Joel D, Souers, Andrew J, Boghaert, Erwin R, Hickson, Jonathan
Cyhoeddwyd yn Pharmacol Res Perspect (2015)

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

gan Phillips, Darren C., Jin, Sha, Gregory, Gareth P., Zhang, Qi, Xue, John, Zhao, Xiaoxian, Chen, Jun, Tong, Yunsong, Zhang, Haichao, Smith, Morey, Tahir, Stephen K., Clark, Rick F., Penning, Thomas D., Devlin, Jennifer R., Shortt, Jake, Hsi, Eric D., Albert, Daniel H., Konopleva, Marina, Johnstone, Ricky W., Leverson, Joel D., Souers, Andrew J.
Cyhoeddwyd yn Leukemia (2019)

Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors

gan Tong, Yunsong, Florjancic, Alan S., Clark, Rick F., Lai, Chunqiu, Mastracchio, Anthony, Zhu, Gui-dong, Smith, Morey L., Kovar, Peter J., Shaw, Bailin, Albert, Daniel H., Qiu, Wei, Longenecker, Kenton L., Liu, Xiaoqin, Olson, Amanda M., Osterling, Donald J., Tahir, Stephen K., Phillips, Darren C., Leverson, Joel D., Souers, Andrew J., Penning, Thomas D.
Cyhoeddwyd yn ACS Med Chem Lett (2021)

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X(L) Inhibitor

gan Wang, Le, Doherty, George A., Judd, Andrew S., Tao, Zhi-Fu, Hansen, T. Matthew, Frey, Robin R., Song, Xiaohong, Bruncko, Milan, Kunzer, Aaron R., Wang, Xilu, Wendt, Michael D., Flygare, John A., Catron, Nathaniel D., Judge, Russell A., Park, Chang H., Shekhar, Shashank, Phillips, Darren C., Nimmer, Paul, Smith, Morey L., Tahir, Stephen K., Xiao, Yu, Xue, John, Zhang, Haichao, Le, Phuong N., Mitten, Michael J., Boghaert, Erwin R., Gao, Wenqing, Kovar, Peter, Choo, Edna F., Diaz, Dolores, Fairbrother, Wayne J., Elmore, Steven W., Sampath, Deepak, Leverson, Joel D., Souers, Andrew James
Cyhoeddwyd yn ACS Med Chem Lett (2020)

Discovery of a Potent and Selective BCL-X(L) Inhibitor with in Vivo Activity

gan Tao, Zhi-Fu, Hasvold, Lisa, Wang, Le, Wang, Xilu, Petros, Andrew M., Park, Chang H., Boghaert, Erwin R., Catron, Nathaniel D., Chen, Jun, Colman, Peter M., Czabotar, Peter E., Deshayes, Kurt, Fairbrother, Wayne J., Flygare, John A., Hymowitz, Sarah G., Jin, Sha, Judge, Russell A., Koehler, Michael F. T., Kovar, Peter J., Lessene, Guillaume, Mitten, Michael J., Ndubaku, Chudi O., Nimmer, Paul, Purkey, Hans E., Oleksijew, Anatol, Phillips, Darren C., Sleebs, Brad E., Smith, Brian J., Smith, Morey L., Tahir, Stephen K., Watson, Keith G., Xiao, Yu, Xue, John, Zhang, Haichao, Zobel, Kerry, Rosenberg, Saul H., Tse, Chris, Leverson, Joel D., Elmore, Steven W., Souers, Andrew J.
Cyhoeddwyd 2014